Citigroup Maintains Buy on Akero Therapeutics, Lowers Price Target to $78

BenzingaMay 13 15:16 ET · Ratings

Akero Therapeutics Analyst Ratings

BenzingaMay 13 15:16 ET · Ratings

Mineralys Therapeutics Analyst Ratings

BenzingaMay 13 08:20 ET · Ratings

Where Liquidia Stands With Analysts

BenzingaMay 12 09:00 ET

Akero Therapeutics GAAP EPS of -$0.90 Beats by $0.12

Seeking AlphaMay 12 07:21 ET

Akero Therapeutics Q1 2025 EPS $(0.90) Beats $(0.99) Estimate, Cash, Cash Equivalents, And Short- And Long-term Marketable Securities As Of March 31, 2025, Were $1.128B, Will Be Sufficient To Fund Its Current Operating Plan Into 2028

BenzingaMay 12 07:20 ET